Korea South
Mediwhale is an AI-empowered health diagnostics startup that utilizes non-invasive retina scans to prevent heart and kidney diseases. Its Reti-Intelligence suite employs deep learning algorithms to identify disease risks before symptoms manifest. Founded in 2016 in South Korea, the company is dedicated to making preventative care more affordable, accessible, safe, and convenient. With product approvals in 8 territories in Europe and Asia, including the EU, UK, Australia, and Korea, and with an FDA approval pending, Mediwhale has garnered significant attention from investors.
Notably, the company recently secured a $9.00M Series A investment on 18 April 2023 from a distinguished group of investors including the Mayo Clinic, Woori Venture Partners, IPS Ventures, BNK Venture Capital, MedAxiom, Innopolis Partners, SBI Investment Korea, Arizona State University, HealthTech Arkansas, and HeartX. This substantial investment reflects the confidence and interest that prominent institutions and venture capital firms have in Mediwhale's pioneering approach to healthcare innovation.
With its expanding footprint and progressive technology, Mediwhale presents a promising opportunity for investors seeking to capitalize on advancements in preventative healthcare and AI-driven diagnostics within the Health Care industry.
